Regulatory Jobs

Why Targeted Protein Degraders Need a Different Kind of CMC Regulatory Reviewer

PROTACs and molecular glues are reviewed as small molecules but behave like a new modality. Here's what that means for CMC regulatory hiring.

Connor Griggs

Connor GriggsMSRACQA

Founder & Editor-in-Chief

9 min read

Introduction

Targeted protein degraders — PROTACs (proteolysis-targeting chimeras) and molecular glues — are a modality that doesn't sit comfortably in either of the two regulatory playbooks most CMC teams already know. They're small molecules, chemically, which means they get filed as drugs rather than biologics. But the way they work, and the way they're made, breaks enough of the assumptions behind a typical small-molecule CMC strategy that sponsors building programs around this class are discovering they need people who can hold both playbooks in their head at once.

This is a look at what makes these molecules harder to develop from a CMC and regulatory standpoint, and what that's starting to mean for hiring.

What a Protein Degrader Actually Is

A classic small-molecule drug usually works by binding to a target protein and blocking or activating it directly — occupying a site and staying there. A PROTAC works differently: it's a bifunctional molecule, built from two binding "warheads" connected by a chemical linker. One end binds the disease-relevant target protein; the other end binds an E3 ubiquitin ligase, a cellular machine that tags proteins for destruction. By bringing the two together, the PROTAC recruits the cell's own disposal system to break down the target protein entirely, rather than just blocking its activity.

Molecular glues work on a related principle — stabilizing an interaction between a target protein and a ligase — but are typically smaller, single-moiety molecules rather than the warhead-linker-warhead architecture of a classic PROTAC. Both classes share the same practical consequence for CMC teams: because degradation is catalytic rather than purely occupancy-driven, a single drug molecule can facilitate the destruction of multiple copies of its target before it's cleared, which changes dosing and exposure assumptions in ways a standard small-molecule program doesn't have to think through.

Why the Chemistry Breaks the Usual Small-Molecule Assumptions

Most oral small-molecule drugs are designed within the rough boundaries of Lipinski's Rule of Five — molecular weight under about 500, limited hydrogen bond donors and acceptors, and so on — because molecules within that space tend to have workable solubility and permeability. PROTACs are built from two warheads and a linker, which routinely pushes their molecular weight well beyond that range. That single fact cascades into almost every CMC workstream:

  • Solubility and formulation become harder problems. Many degraders need specialized formulation approaches — amorphous solid dispersions, lipid-based formulations, or particle engineering — to achieve adequate oral bioavailability, rather than the more conventional formulation toolkit that works for smaller molecules.
  • Synthetic routes are longer and more complex, often involving convergent synthesis of two warhead fragments followed by linker conjugation, which introduces more steps where impurities can form and more intermediates that need their own characterization and control strategy.
  • Impurity profiles look different, with degradation-related and linker-related impurities that don't map onto the impurity classes analytical and toxicology teams are used to evaluating for conventional small molecules.
  • Analytical characterization is harder, since standard small-molecule analytical methods weren't built with molecules this large and conformationally flexible in mind, and establishing a stability-indicating method can take real method-development work rather than adapting an existing platform method.

The Regulatory Pathway: Familiar Forms, Unfamiliar Content

In the US, protein degraders are reviewed as small-molecule drugs, which means they go through the IND and NDA pathway rather than the BLA pathway used for most biologics. The submission format — the Common Technical Document — is the same one CMC and regulatory teams already know. What's different is the content sponsors have to put into that familiar format, and the fact that there is, as of this writing, no dedicated FDA guidance document specific to protein degraders the way there is for, say, cell and gene therapies or monoclonal antibodies.

That absence of modality-specific guidance means sponsors are largely extrapolating from general ICH quality guidelines — ICH Q6A for specifications, ICH Q3A/B for impurities — and from whatever precedent exists in prior degrader approvals and public regulatory interactions, rather than following a playbook written for this exact class. Regulatory CMC strategists on these programs spend real time in scientific advice meetings and pre-IND interactions specifically working through how general principles should apply to a molecule type the guidance wasn't written with in mind. This is honest uncertainty, not a settled area, and anyone sizing up this niche should go in understanding that the regulatory expectations are still being worked out case by case rather than codified.

What This Means for Hiring

The practical effect of all this is that companies building degrader pipelines are looking for people who sit at the intersection of a few skill sets that don't always come packaged together:

  • CMC regulatory specialists who understand small-molecule submission mechanics but are also conversant in degrader pharmacology — catalytic versus stoichiometric mechanism, ternary complex formation, and what that means for the arguments a sponsor needs to make about dose and exposure.
  • Formulation scientists with specific experience in poorly soluble, high-molecular-weight small molecules, since the standard formulation toolkit often isn't sufficient on its own.
  • Analytical chemists who can develop and validate methods for larger, more complex, more conformationally flexible molecules than a typical small-molecule analytical group is used to characterizing.
  • Regulatory strategists comfortable building a scientific advice or pre-IND argument from general principles rather than pointing to an existing modality-specific guidance document.

Where the Demand Is Concentrating

Hiring in this niche is concentrated in two places: biotechs built specifically around degrader or targeted-protein-degradation platforms, and the contract development and manufacturing organizations (CDMOs) building out dedicated capability to serve them. Larger pharmaceutical companies with internal degrader programs are also hiring, but often by moving existing small-molecule CMC staff onto these programs and building the specialized knowledge internally, rather than hiring purely from the outside for every role.

It's worth being candid that this remains a comparatively small niche relative to established modalities like conventional small molecules, monoclonal antibodies, or even cell and gene therapy. The number of approved degrader products is still limited, and the pipeline, while active, is concentrated in a relatively small number of companies. This is a genuine, growing area of specialized demand — but it is not yet a large-volume hiring category, and candidates should weigh that honestly against more established CMC career paths.

How People Move Into This Work

There isn't yet a dedicated academic or certification pathway into protein degrader CMC work, because the field is too young and too small for one to have formed. The realistic entry points are lateral moves: small-molecule CMC regulatory professionals who take on a degrader program within their existing company and build the specialized knowledge on the job, formulation scientists with a track record on other poorly soluble compounds who get pulled onto a degrader project because the underlying problem looks familiar, and analytical chemists with experience characterizing complex, flexible molecules in other contexts — including, for some, prior work on peptides or bioconjugates, which share some of the same analytical headaches even though the chemistry is otherwise quite different.

For someone early in a CMC or regulatory career who finds this area genuinely interesting, the more realistic near-term move is building strong fundamentals in small-molecule CMC and analytical chemistry first, then actively seeking out a degrader-focused project or company once that foundation is solid, rather than trying to enter the niche directly.

Questions Worth Asking Before Joining a Degrader Program

Because the field is young and concentrated in a relatively small number of companies, due diligence before joining a degrader-focused role matters more than it would for a role on an established small-molecule program. Worth asking directly in an interview: how many candidate molecules has the company actually advanced into IND-enabling studies, not just discovery-stage screening; whether the CMC and analytical groups have in-house degrader-specific experience or are building that capability from scratch alongside you; and how the company is resourcing formulation work given how often solubility becomes the limiting factor for these molecules. None of these questions are hostile — they're exactly the kind of specific, informed questions a hiring manager in this space expects and respects from a serious candidate, and the answers tell you a great deal about whether the program is further along than its public pipeline slide suggests, or earlier.

A Familiar Pattern in Novel-Modality Hiring

This isn't the first time a new chemistry class has outpaced the regulatory framework built to review it. Antibody-drug conjugates went through a similar period where CMC teams had to reconcile small-molecule payload chemistry with biologic antibody manufacturing before enough precedent accumulated for the review process to feel routine. Bispecific antibodies forced a parallel rethink of comparability assessment as manufacturing changes became harder to evaluate against a single reference standard. In both cases, the specialized hiring demand peaked while the science was still ahead of settled guidance, and gradually normalized as agencies published clearer expectations and more approvals built up a track record. Protein degraders appear to be tracking a similar arc, which is useful context for anyone deciding whether to specialize now, while the work is more exploratory and less standardized, or wait until the pathway is better defined and the day-to-day work looks more routine.

Conclusion

Targeted protein degraders are a reminder that new drug modalities don't always arrive with a new regulatory pathway attached. Sometimes they arrive inside an old pathway that wasn't built with them in mind, and the specialized expertise that develops around them lives in the judgment calls people make filling that gap — in formulation, in analytical method development, and in the regulatory conversations where general principles get applied to a molecule type nobody had fully anticipated when those principles were written.

Regulatory & Quality. REWIRED.

New roles. Real pay. Your next move.

  • Hand-picked roles, every week.
  • The newest company pages.
  • One article worth your time.
Get the Weekly

Free. Thursday mornings. One-click unsubscribe.

Connor GriggsConnor Griggs

About the author

Connor GriggsMSRA, CQA

Founder & Editor-in-Chief

Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.

Find your next regulatory or quality role

Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.

Next in Market InsightsUS Regulatory Affairs Salaries in 2025